Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study

Topolyanskaya, Svetlana V; Rachina, S.A.; Lytkina, Karine A.; Melkonyan, Georgiy G.; Savochkina, Yulia A

Главная
→
Медицинский журнал Западного Казахстана
→
2024 year
→
West Kazakhstan Medical Journal Volume 66 Issue 4
→
Просмотр элемента

dc.contributor.author	Topolyanskaya, Svetlana V
dc.contributor.author	Rachina, S.A.
dc.contributor.author	Lytkina, Karine A.
dc.contributor.author	Melkonyan, Georgiy G.
dc.contributor.author	Savochkina, Yulia A
dc.date.accessioned	2025-01-13T08:11:34Z
dc.date.available	2025-01-13T08:11:34Z
dc.date.issued	2024-12-20
dc.identifier.other	DOI: 10.18502/wkmj.v66i4.17780
dc.identifier.uri	http://localhost:8080/xmlui/handle/123456789/429
dc.description	A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a significant reduction in body temperature, decrease in CRP, and an increase in the levels of blood cells. Revealed clinical improvement was seen in 69.7% of cases, 8.5% of patients showed deterioration in their condition and were transferred to the ICU, 13.6% died. Olokizumab was well tolerated except for slight elevation in live enzymes, such as aspartate transaminase and alanine transaminase.	ru
dc.description.abstract	A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a significant reduction in body temperature, decrease in CRP, and an increase in the levels of blood cells. Revealed clinical improvement was seen in 69.7% of cases, 8.5% of patients showed deterioration in their condition and were transferred to the ICU, 13.6% died. Olokizumab was well tolerated except for slight elevation in live enzymes, such as aspartate transaminase and alanine transaminase.	ru
dc.language.iso	en	ru
dc.publisher	West Kazakhstan Medical Journal	ru
dc.subject	COVID-19	ru
dc.subject	C-reactive protein	ru
dc.subject	interleukin-6	ru
dc.subject	olokizumab How	ru
dc.title	Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study	ru
dc.type	Article	ru